Glycomine Secures $12,000,000 Series A Funding Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=84e595a1-5813-417e-82bf-bad25262f982 - Date
11/17/2016 - Company Name
Glycomine - Mailing Address
953 Indiana Street San Francisco, CA 94107 USA - Company Description
Glycomine is developing orphan drugs for serious rare monogenic disorders of metabolism and protein misfolding for which no other therapeutic options exist. - Website
http://www.glycomine.com - Transaction Type
Venture Equity - Transaction Amount
$12,000,000 - Transaction Round
Series A - Proceeds Purposes
Glycomine will use the proceeds from this financing to complete IND enabling pre-clinical studies and initiate clinical studies of its substrate replacement therapy in patients with Congenital Disorder of Glycosylation Type Ia (CDG-Ia), and to accelerate discovery efforts towards an enzyme replacement therapy for N-glycanase deficiency (Ngly1). - M&A Terms
- Venture Investor
Sanderling Ventures - Venture Investor
Chiesi Ventures
